Ferroptosis in cancer cells triggers PGE2 production for tumour immune escape
Ferroptosis, a form of cell death induced by overwhelming membrane lipid peroxidation, is a vulnerability of many cancers, including cancers resistant to current molecular and immune-based therapies 1–7 . Triggering of ferroptosis therefore provides an opportunity to achieve elimination of difficult-to-treat cancers 1–4,8,9 . Studies in mouse cancer models have demonstrated that anticancer immunity, mediated by dendritic cells (DCs) and CD8 + T cells, is essential for effective tumour eradication by ferroptosis-inducing strategies 10–13 . However, ferroptotic cells limit this response 8–10,14 , resulting in immune escape and tumour growth through mechanisms that remain unclear. Here we demonstrate that ferroptotic cancer cells activate a molecular program resulting in aberrant production of prostaglandin E 2 (PGE 2 ), which limits the stimulation of anticancer CD8 + T cell responses by type 1 conventional DCs (cDC1s), thereby promoting immune escape. In ferroptotic cancer cells, lipid peroxidation-mediated membrane permeabilization enables Ca 2+ influx, which activates p38 MAPK signalling and thereby drives PGE 2 production. This signalling axis is uncoupled from cancer cell death and can be targeted to selectively interfere with immune-inhibitory PGE 2 production while preserving ferroptotic cancer cell elimination. In the context of cancer cell ferroptosis, ablation of PGE 2 production or disrupting PGE 2 signalling restores cDC1-mediated anticancer CD8 + T cell responses and leads to effective tumour elimination. Our findings identify a key mechanism that limits antitumour immunity and prevents tumour elimination upon ferroptosis induction in cancer cells, which could be exploited for cancer therapy.
Authors
- Anna Hirschberger
- Lukas Ramsauer (ORCID: https://orcid.org/0000-0002-0774-5203)
- Silvia von Karstedt (ORCID: https://orcid.org/0000-0002-7816-5919)
- Marcus Conrad (ORCID: https://orcid.org/0000-0003-1140-5612)
- Jan P. Böttcher (ORCID: https://orcid.org/0000-0002-8163-8107)
- Gabriela Maria Wiedemann (ORCID: https://orcid.org/0000-0001-6138-9791)
- Scott J. Dixon (ORCID: https://orcid.org/0000-0001-6230-8199)
- Julia Esser‐von Bieren (ORCID: https://orcid.org/0000-0003-1898-9382)
- Christina M. Bebber (ORCID: https://orcid.org/0000-0002-7841-7493)
- Nicolas Snaidero (ORCID: https://orcid.org/0000-0003-1148-6926)
- Kevin Schmid
- Toshitaka Nakamura (ORCID: https://orcid.org/0000-0002-4248-2058)
- Gregor Ebert (ORCID: https://orcid.org/0000-0002-5318-3037)
- Percy Alexander Knolle (ORCID: https://orcid.org/0000-0003-2983-0414)
- Anna‐Marie Pedde
- Sainitin Donakonda (ORCID: https://orcid.org/0000-0003-3216-8759)
- Martina Anton (ORCID: https://orcid.org/0000-0001-5290-5213)
- Felix Bayerl (ORCID: https://orcid.org/0000-0002-4737-1808)
- Benedikt Spitzlberger (ORCID: https://orcid.org/0009-0005-5791-5118)
- Sebastian B. Lacher (ORCID: https://orcid.org/0000-0002-1571-6015)
- Nadine Nuschele
- María Parra Reyes
- Daina Chakma
Institutions
- University of Cologne (DE)
- Tohoku University (JP)
- TUM Klinikum (DE)
- Helmholtz Zentrum München (DE)
- Universitätsklinikum Tübingen (DE)
- Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (DE)
- Hertie Institute for Clinical Brain Research (DE)
- University Hospital Cologne (DE)
- Technical University of Munich (DE)
- University of Tübingen (DE)
- Stanford University (US)
- University of Lausanne (CH)
Publication Details
- Journal
- Nature
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1038/s41586-026-11333-6
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission
- Deutsche Forschungsgemeinschaft
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Eberhard Karls Universität Tübingen
- HORIZON EUROPE Framework Programme